ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):337-341.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]





Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation
重庆医科大学附属第二医院心血管内科,重庆 400010
ZHANG RuoyuYIN Yuehui
Department of Cardiology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China
糖尿病 心房颤动 心房重构 降糖药物
Diabetic mellitus Atrial fibrillation Atrial remodelling Diabetic drugs
糖尿病作为心血管疾病的重要风险因素,也是老年人群中常见的慢性疾病之一。大部分心血管疾病如冠心病、高血压、心肌病等随着病程的进展往往可发展为心房颤动。已有证据显示,糖尿病可通过影响心脏的自主神经重构、电重构及结构重构诱发心房颤动; 而在糖尿病患者中,心房颤动也是其全因死亡率和心血管发病率的独立危险因素。了解糖尿病在心房颤动发病中的作用及各种降糖药对心房颤动的影响将有助于理解糖尿病和心房颤动的相关性,并更好地对合并心房颤动的糖尿病患者进行管理。
Diabetic mellitus is one of the most common chronic diseases for the senior population and presents one of the most important risk factors for cardiovascular disease. Most cardiovascular disease such as coronary artery disease, hypertension and cardiomyopathy will develop to atrial fibrillation(Af)with the progress of primary disease. Evidence has proven that Af is a strong and independent cause of death and cardiovascular morbidity in diabetic patients. Additionally that diabetic mellitus could promote the initiation and maintenance of Af by causing the autonomic, electrical and structural remodelling of the atrium. It will help us to understand the relationship between diabetic mellitus and Af and make better decisions regarding the management of these patients by reviewing the potential pathology of Af in the setting of diabetic and the influence of current available anti-diabetic drugs to Af.


[1] Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet,2011,378(9785):31-40.
[2] Lin Y, Li H, Lan X, et al. Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus[J]. Sci World J,2013,2013: 209428.
[3] Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression[J]. Circ Res,2014,114(9):1483-1499.
[4] Miki T, Yuda S, Kouzu H, et al. Diabetic cardiomyopathy:pathophysiology and clinical features[J]. Heart Fail Rev,2013,18(2):149-166.
[5] Ayhan S, Ozturk S, Alcelik A, et al. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose[J]. J Interv Card Electrophysiol,2012,35(3): 247-252; discussion 252.
[6] Akyel A, Oksuz F, Karadeniz M, et al. Atrial electromechanical delay in type 2 diabetes mellitus[J]. Wien Klin Wochenschr,2014,126(3-4):101-105.
[7] Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose[J]. Am J Cardiol,2010,106(11):1615-1620.
[8] Kadappu KK, Boyd A, Eshoo S, et al. Changes in left atrial volume in diabetes mellitus:more than diastolic dysfunction[J]. Eur Heart J Cardiovasc Imaging,2012,13(12):1016-1023.
[9] Liu C, Fu H, Li J, et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits[J]. Anadolu Kardiyol Derg,2012,12(7):543-550.
[10] Goudis CA, Korantzopoulos P, Ntalas IV, et al. Diabetes mellitus and atrial fibrillation:pathophysiological mechanisms and potential upstream therapies[J]. Int J Cardiol,2015,184:617-622.
[11] Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation[J]. Circulation,2012,125(2): 216-225.
[12] Guo L, Jiang F, Tang YT, et al. The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease[J]. Diabetes Technol Ther,2014,16(4):224-234.
[13] Gong X, Wang P, Wu Q, et al. Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W)transgenic mouse of dilated cardiomyopathy[J]. Eur J Cell Biol,2016,95(1):57-67.
[14] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J]. Diabetes Care,2012,35(6):1364-1379.
[15] Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus:a population-based dynamic cohort and in vitro studies[J]. Cardiovasc Diabetol,2014,13:123.
[16] Azimova K, San JZ, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs[J]. Ochsner J,2014,14(4):616-632.
[17] Yamazaki M, Avula UM, Bandaru K, et al. Acute regional left atrial ischemia causes acceleration of atrial drivers during atrial fibrillation[J]. Heart Rhythm,2013,10(6):901-909.
[18] Latini R, Staszewsky L, Sun JL, et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance:the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial[J]. Am Heart J,2013,166(5):935-940.e1.
[19] Gu J, Liu X, Wang QX, et al. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models[J]. J Mol Cell Cardiol,2013, 65:1-8.
[20] Gu J, Hu W, Liu X. Pioglitazone improves potassium channel remodeling induced by angiotensin Ⅱ in atrial myocytes[J]. Med Sci Monit Basic Res,2014,20:153-160.
[21] Liu B, Wang J, Wang G. Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients[J]. Int Heart J,2014,55(6):499-505.
[22] Swartz MF, Fink GW, Sarwar MF, et al. Elevated pre-operative serum peptides for collagen Ⅰand Ⅲsynthesis result in post-surgical atrial fibrillation[J]. J Am Coll Cardiol,2012,60(18):1799-1806.
[23] Xu D, Murakoshi N, Igarashi M, et al. PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model[J]. J Cardiovasc Electrophysiol,2012,23(2):209-217.
[24] Liu T, Zhao H, Li J, et al. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits[J]. Cardiovasc Ther,2014,32(4):178-183.
[25] Chao TF, Leu HB, Huang CC, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes[J]. Int J Cardiol,2012,156(2):199-202.
[26] Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus[J]. Europace,2011,13(9):1256-1261.
[27] Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy[J]. Curr Diab Rep,2014,14(5):483.
[28] Zheng MY, Yang JH, Shan CY, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report[J]. Cardiovasc Diabetol,2013,12:73.
[29] Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials[J]. Diab Vasc Dis Res,2015,12(2):90-100.
[30] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015,373(22):2117-2128.


 ZHANG Yuan,WANG Qunshan.Advance of Research about Dabigatran Etexliate in Organic Heart Disease with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.008]
 YANG Zhen,LI Jing,JIA Shaobin.Identification of Atrial Fibrillation in Patients with Cryptogenic Stroke[J].Advances in Cardiovascular Diseases,2016,(4):69.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.018]
 ZHENG Tao,LING Zhiyu.Epicardial Adipose Tissue and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
[4]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
 HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(4):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[5]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
 XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
 FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[7]张明 王敬萍.Nur77和GRP78与糖尿病心肌缺血再灌注损伤的关系研究[J].心血管病学进展,2020,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
 ZHANG Ming Wang Jingping.Relationship between Nur77 and GRP78 and Myocardial Ischemia-reperfusion Injury in Diabetic Patients[J].Advances in Cardiovascular Diseases,2020,(4):571.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.003]
[8]麦尔耶姆·瓦热斯 罗心平 周鹏.糖尿病与心力衰竭:2型糖尿病是心力衰竭的独立危险因素?[J].心血管病学进展,2020,(7):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
 Maieryemu·Waresi,LUO Xinping,ZHOU Peng.Diabetes and Heart Failure: Is Type 2 Diabetes an Independent Risk Factor for Heart Failure?[J].Advances in Cardiovascular Diseases,2020,(4):681.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.002]
[9]廖丽萍 周跟东 张晓红.血清甘油三酯葡萄糖乘积指数与代谢性疾病的研究进展[J].心血管病学进展,2020,(11):1189.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[10]高婧晗 刘飞 杨晓蕾 夏云龙.钙离子稳态的调控在糖尿病相关心房颤动中的作用[J].心血管病学进展,2021,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]
 GAO Jinghan,LIU Fei,YANG Xiaolei,et al.Regulation of Calcium Homeostasis in Diabetes-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):888.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.006]


作者简介:张若愚(1990—),在读硕士,主要从事心房颤动研究。Email:zrycqmu@163.com 通信作者:殷跃辉(1963—),主任医师,博士生导师,硕士,主要从事心律失常及电生理研究。Email:yinyh63@163.com
更新日期/Last Update: 2016-07-25